17 results
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
studies evaluating Frataxin and CTI-1601’s effects on a model of neurodegeneration June 12 – 15, 2022 XXIV World Congress International Society for Heart
DEFM14A
LRMR
Larimar Therapeutics Inc
29 Apr 20
Proxy related to merger
3:20pm
School at the University of Pennsylvania. He is a member of the Licensing Executives Society and is a Certified Public Accountant, Certified Management
PRER14A
LRMR
Larimar Therapeutics Inc
10 Apr 20
Preliminary revised proxy
4:38pm
of the Licensing Executives Society and is a Certified Public Accountant, Certified Management Accountant and a Certified Licensing Professional.
Related Person
PREM14A
LRMR
Larimar Therapeutics Inc
6 Mar 20
Preliminary proxy related to merger
5:32pm
of the Licensing Executives Society and is a Certified Public Accountant, Certified Management Accountant and a Certified Licensing Professional.
Related
8-K
EX-2.1
rkmcdk0ww1nnb26p
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
DEFA14A
EX-2.1
2zozuxlkn1t2dm63
18 Dec 19
Additional proxy soliciting materials
8:11am
8-K
EX-99.1
chyhixralgtmngce1 77
30 May 18
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
5:17pm
10-K
wejfkc5
25 Mar 15
Annual report
12:00am
424B4
2jjxyv1
23 Jan 15
Prospectus supplement with pricing info
12:00am
424B4
4w0 o5l8pkr
19 Jun 14
Prospectus supplement with pricing info
12:00am
S-1
wegptp9q
18 Apr 14
IPO registration
12:00am
- Prev
- 1
- Next